GlassScriptPhysician profile
Vinesha Byers
NPI 1487177523
$10,093.61
in general payments reported to CMS, 2019-2025
30 companies · $3,518 in 2025
The $3,518 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5.00 · 2022: $241 · 2023: $2,400 · 2024: $3,929 · 2025: $3,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,345 · Education: $502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,345.14 |
| Education | $502.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,942.42 | 2022-2025 | |
| Janssen Biotech, INC. | $964.97 | 2022-2025 | Tremfya |
| Pfizer INC. | $685.43 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $646.83 | 2022-2025 | Winlevi, Ilumya, Blu-U |
| Dermavant Sciences, INC. | $614.77 | 2023-2024 | Vtama |
| Lilly USA, LLC | $573.09 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Amgen INC. | $552.98 | 2023-2025 | Otezla, Otezla |
| Ucb, INC. | $549.44 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $528.77 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $462.82 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $445.90 | 2023-2025 | |
| Incyte Corporation | $383.58 | 2022-2025 | Opzelura |
| Kerecis Limited | $321.44 | 2023-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Mayne Pharma Commercial LLC | $302.91 | 2023-2025 | |
| Genzyme Corporation | $301.28 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $168.15 | 2023-2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $131.19 | 2024-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.57 | 2022-2025 | Cabtreo, Arazlo |
| Leo Pharma INC. | $77.46 | 2022-2025 | Adbry, Anzupgo |
| Organon LLC | $76.57 | 2023-2025 | Vtama |
| Galderma Laboratories, L.P. | $66.59 | 2024-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.55 | 2024 | Spevigo |
| Mylan Institutional INC. | $36.41 | 2023 | Hulio |
| Almirall LLC | $29.54 | 2023 | Seysara |
| Biofrontera INC. | $24.52 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Revance Therapeutics, INC. | $23.65 | 2024 | Daxxify |
| Convatec INC. | $18.90 | 2024 | |
| Mallinckrodt Hospital Products INC. | $16.49 | 2025 | Acthar |
| Genentech USA, INC. | $15.95 | 2025 | Xolair |
| Verrica Pharmaceuticals INC. | $14.44 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinesha Byers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.